Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% Higher - Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) were up 6.5% on Thursday . The company traded as high as $19.13 and last traded at $19.46. Approximately 16,710 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 237,331 shares. The stock had previously closed at $18.27.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DNTH. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating for the company. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Stock Down 9.3 %

The stock has a market cap of $582.75 million, a price-to-earnings ratio of -7.26 and a beta of 1.82. The company has a 50 day simple moving average of $21.91 and a 200 day simple moving average of $24.24.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. R Squared Ltd bought a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $26,000. Quest Partners LLC raised its holdings in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $59,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.